Abstracting and Indexing

• PubMed NLM
• Google Scholar
• Semantic Scholar
• Scilit
• CrossRef
• WorldCat
• ResearchGate
• Academic Keys
• DRJI
• Microsoft Academic
• Academia.edu
• OpenAIRE
• Scribd
• Baidu Scholar

East Asia has the highest incidence rates of gastric cancer, making it a major worldwide health problem. For resectable illness, surgical resection is still the mainstay of curative treatment; nevertheless, there is ongoing discussion on the best time to provide chemotherapy, whether it should be administered as an adjuvant or neoadjuvant before surgery. The ability of neoadjuvant chemotherapy to downstage tumours, raise R0 resection rates, and treat micro metastatic illness early has made it popular. This method is becoming more and more popular for treating regionally advanced gastric cancer in several Western countries after multiple trials demonstrated equivalent or better overall survival outcomes. Conversely, adjuvant chemotherapy is still often used, especially in East Asia, where seminal studies like ACTS-GC and CLASSIC have shown how effective it is at enhancing both overall and disease-free survival. It is frequently preferred for patients with early-stage illness or when impaired dietary or physical health makes preoperative therapy impractical. In the end, there are substantial oncological advantages across both neoadjuvant and adjuvant treatments. The patient's condition, the tumour’s features, and the institution's experience should all be considered while choosing a treatment. A multidisciplinary approach is still crucial for optimising results, considering changing evidence, and further research will assist in sequestering the best course of action for different patient subgroups.